← Back to patent-cliff list
CBP-501
Tier C — Watch / tradeCBP-501
Canbas Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Checkpoint kinase 2, CHEK1
Indications (approved)：Pancreatic cancer, Non-small cell lung cancer, 间皮组织肿瘤, Solid tumour
Regional status
US
Phase II
2008-05-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CBP-501?
Approved indications include: Pancreatic cancer, Non-small cell lung cancer, 间皮组织肿瘤, Solid tumour.
When does the CBP-501 patent expire?
No public expiry year is available for CBP-501 yet; this page updates once verified.
How do I get a quote for CBP-501 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22